Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsReporting bias in medical research - a narrative reviewComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsDiscrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysisComparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimatesSulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewEffect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular safety of anti-diabetic drugsDiabetes Drugs and Cardiovascular SafetyReport of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer, Second reportPPARs: Protectors or Opponents of Myocardial Function?Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirementsInsulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studiesCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsNetwork-based approaches in drug discovery and early developmentDeciding oral drugs after metformin in type 2 diabetes: An evidence-based approachSomething old, something new and something very old: drugs for treating type 2 diabetesCardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapiesTreating the elderly diabetic patient: special considerationsSystematic reviews to ascertain the safety of diabetes medicationsEfficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59,197 participants in 9 randomized controlled trialsHuman obesity and endothelium-dependent responsivenessShould antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?Glycemic control and cardiovascular disease: what's a doctor to do?PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Current perspectives on cardiovascular outcome trials in diabetesHeart Failure: a Major Cardiovascular Complication of Diabetes MellitusStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseA Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease.Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondMetabolic shifts during aging and pathologyEffect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trialsBreast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled TrialsA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
P2860
Q21144611-D553EDED-D590-493B-AC59-A14A79207EBFQ21203744-AFABB4FF-7008-4CD6-9942-5C93BB848D83Q22241134-BE726495-68B4-42C0-8899-7C116FD33ECEQ22306551-597DD88F-7189-43BD-A339-23611125D0D0Q24186056-2C58EACC-5BE0-44C1-B694-125368A374BEQ24186660-42C12DE0-111A-45C0-ADA4-5751570EF550Q24197884-15996E2E-65B2-4C5E-93D8-BD8FB3932736Q24235718-80EF1A9B-FA46-4074-B56F-2884D7C9F6FBQ24240522-56BBA0A1-DAE3-4E5B-A2ED-58F5A2D9BCDFQ24561401-2035D9FE-2824-4E9E-9CE4-A66404E1C0A5Q24628988-BA443237-0162-457A-AB1F-6B98AC68612BQ26740253-6D2397BE-C797-4263-8F9E-E2E50AB75885Q26741082-D9C0446E-FF74-49EF-BF68-E50CAB8A7EF9Q26746085-98E4A5B9-C116-4557-A707-AE7D61D35DF3Q26749362-9478E5AC-2086-4DFB-8909-B0B03CCAD3AEQ26771753-754E9D30-2831-400B-9671-45E2194A4CC9Q26801121-16282002-A7C5-4250-9A9A-8BEF66335960Q26823071-34CC9EDB-58C8-4CC0-9F13-8916DA6A9144Q26824616-52E6DEF1-C665-4D49-B59D-1A1ED2E39AE3Q26827940-31B933BA-AED7-45FA-9A2E-62B2CC3382C2Q26851797-86263C87-7B41-486E-B319-845C08995A45Q26865663-78EDCF3F-177F-4EF9-BE3D-D48D223D16F3Q26866958-BA4F6BA8-E3D5-4698-93CC-5B92D1FF8370Q26995176-8130C266-F0A7-4B3A-8496-FDB0D7CA9754Q27000766-7E39D9E1-2DD4-4055-9D09-5A22473E0FA9Q27008807-8BE0E34B-C4D4-487E-8237-A470E2B7041EQ27021665-C6E5B16C-7781-43B6-90DC-F8E87E4831C2Q27022813-E64E96AC-A7B2-4B40-BE6B-D4460E301DC7Q27024469-97A95ED7-46B8-411B-83AB-CE4F180C3C67Q27024799-09626237-5D3A-40B8-8EC6-6FFDF61F85F6Q27687851-B4EB2761-F8AF-458B-BE11-02CF142F68A2Q28066006-842B1DF4-72EA-4C2F-9433-94E536C62773Q28066310-C669FCED-70C0-4504-AD25-0BD03375CD38Q28069065-12276F4D-948A-48F2-A4D7-683FE68FF09DQ28074377-E02781D6-1D64-4CE7-8C3D-1AFCFCA8EA86Q28075848-2CAD051F-8AF2-427E-AB94-3253D3CE0DA4Q28088313-EAD71EBB-F63A-4581-820E-78AA410D9E47Q28256514-103F70F3-2E27-415F-A57B-D34B360F0286Q28269986-284AA242-9F77-4EEE-93C0-3F45016F1A50Q28282265-26C58D8B-620F-4634-B230-91D263BB1C31
P2860
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@ast
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@en
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@nl
type
label
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@ast
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@en
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@nl
prefLabel
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@ast
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@en
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@nl
P2093
P50
P921
P1433
P1476
Rosiglitazone evaluated for ca ...... randomised, open-label trial.
@en
P2093
Henning Beck-Nielsen
John J V McMurray
Nigel P Jones
Paula S Curtis
Philip D Home
RECORD Study Team
Ramon Gomis
Stuart J Pocock
P304
P356
10.1016/S0140-6736(09)60953-3
P407
P577
2009-06-06T00:00:00Z